This editorial is here to once again remind us all that objective response rates and progression-free survival, while often endpoints of choice to expect potential drug approvals, are far from demonstrating a history of any reliable correlation with overall survival and such investigations should always include follow-up with reported overall survival outcomes when available. | Merino, J Clin Oncol 2023
